Ann Pharmacother:加巴喷丁治疗呃逆耐受性良好

2013-07-26 MedSci MedSci原创

为了评估加巴喷丁治疗顽固性或持续性呃逆的疗效,来自美国俄克拉荷马州立大学药学院的研究者对MEDLINE(1966年~2013年3月)、Web of Science(1945年~2013年3月)和国际药学文摘(1970年~2013年3月)等数据库进行了相关检索,该数据检索结果于2013年6月刊发在The Annals of pharmacotherapy杂志上。由于持续性或顽固性呃逆的发病率较低,鲜

为了评估加巴喷丁治疗顽固性或持续性呃逆的疗效,来自美国俄克拉荷马州立大学药学院的研究者对MEDLINE(1966年~2013年3月)、Web of Science(1945年~2013年3月)和国际药学文摘(1970年~2013年3月)等数据库进行了相关检索,该数据检索结果于2013年6月刊发在The Annals of pharmacotherapy杂志上。
由于持续性或顽固性呃逆的发病率较低,鲜有药物疗效研究的临床对照试验。因此,大多数数据只是来自病例报告或病例系列。

研究者评估了涉及加巴喷丁治疗持续性或顽固性呃逆的17例病例报告和2个病例系列。所有的病例中加巴喷丁治疗的结果都呈阳性,短期的证据表明了疗效,但在某些病例中,结果常被联合治疗与合并症干扰混淆。病例报告表明,加巴喷丁作为二线药物,可能对卒中康复或姑息治疗中对氯丙嗪有不良反应的患者有用。加巴喷丁耐受性良好,副作用较轻。

最后研究者总结道,加巴喷丁治疗呃逆的耐受性良好,可作为某些特定患者的二线治疗药物。

原始出处:

Thompson DF, Brooks KG.Gabapentin therapy of hiccups. Ann Pharmacother. 2013 Jun;47(6):897-903.

Page RL 2nd, Luna M, Brieke A, Lindenfeld J.Low-dose gabapentin for intractable hiccups in a heart transplant recipient. Prog Transplant. 2011 Dec;21(4):340-3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908156, encodeId=6e101908156da, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 05 18:13:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995884, encodeId=71b61995884dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 13 19:13:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787134, encodeId=06eb1e87134ce, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 12 03:13:00 CST 2013, time=2013-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417619, encodeId=51ab141e61961, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 28 12:13:00 CST 2013, time=2013-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908156, encodeId=6e101908156da, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 05 18:13:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995884, encodeId=71b61995884dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 13 19:13:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787134, encodeId=06eb1e87134ce, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 12 03:13:00 CST 2013, time=2013-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417619, encodeId=51ab141e61961, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 28 12:13:00 CST 2013, time=2013-07-28, status=1, ipAttribution=)]
    2013-10-13 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908156, encodeId=6e101908156da, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 05 18:13:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995884, encodeId=71b61995884dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 13 19:13:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787134, encodeId=06eb1e87134ce, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 12 03:13:00 CST 2013, time=2013-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417619, encodeId=51ab141e61961, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 28 12:13:00 CST 2013, time=2013-07-28, status=1, ipAttribution=)]
    2013-08-12 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908156, encodeId=6e101908156da, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 05 18:13:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995884, encodeId=71b61995884dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 13 19:13:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787134, encodeId=06eb1e87134ce, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 12 03:13:00 CST 2013, time=2013-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417619, encodeId=51ab141e61961, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 28 12:13:00 CST 2013, time=2013-07-28, status=1, ipAttribution=)]

相关资讯

Neurology:加巴喷丁不增加妊娠妇女的胎儿出生缺陷发生率

加巴喷丁是一种新型抗癫痫药,其为γ-氨基丁酸(GABA)的衍生物,但对妊娠妇女的影响尚不明确。来自多伦多大学的Hisaki Fujii等学者进行了此方面的研究发表在2013年4月23日的Neurology杂志上。该观察性研究的目的为:1、明确孕早期应用加巴喷丁是否与新生儿重大出生缺陷相关;2、评估自发性流产、治疗性流产、死胎、分娩时的新生儿的平均出生体重及胎龄;3、评估妊娠晚期暴露后新生儿适应不良